시장보고서
상품코드
1148934

세계의 페닐케톤뇨증 시장 : 출시 및 파이프라인 약제 평가, 임상시험, 경쟁 구도

Phenylketonuria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

발행일: | 리서치사: GlobalData | 페이지 정보: 영문 69 Pages | 배송안내 : 즉시배송

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

페닐케톤뇨증 (Phenylketonuria)시장에 대해 조사했으며, 질환 개요와 함께 출시 및 파이프라인 약제 평가, 임상시험 동향 및 향후 전망 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

  • 질환 개요
  • 역학 개요
  • 치료 개요

제4장 출시 약제 평가

  • 주요 출시 약제
  • 작용기전별 개요
  • 투여 경로별 개요
  • 출시 약제 개요와 판매 예측

제5장 가격 결정과 상환 평가

제6장 파이프라인 약제 평가

  • 3상 파이프라인 의약품
  • 개발 단계별 개요
  • 분자 유형별 개요
  • 작용기전별 개요
  • 투여 경로별 개요
  • 임상 단계 전환 성공률(PTSR) 및 승인 가능성(LoA)
  • 치료 영역 및 적응증별 PTSR 및 LoA

제7장 임상시험 평가

제8장 거래 상황

제9장 상업적 평가

  • 주요 시장 진출기업

제10장 향후의 시장 성장 촉진요인

제11장 부록

LSH 22.11.18

This reports provides a data-driven overview of the current and future competitive landscape in Phenylketonuria therapeutics.

Synopsis

  • In 2022, there will be more than 500,000 diagnosed prevalent cases of PKU across 16 pharmaceutical markets.
  • There are only two leading marketed drugs for the treatment of PKU, both from BioMarin Pharmaceutical.
  • R&D activity in PKU is relatively low, with two products in Phase III development.
  • Of the 56 trials investigating PKU that were initiated over the past 10 years, nearly 18% were Phase III trials.
  • In deals involving companies with PKU assets, partnerships and licensing agreements are the most common type of deal globally.
  • Commercial launch of sepiapterin from PTC Therapeutics is expected in the US and EU in Q4 2023.

Scope

GlobalData's Phenylketonuria: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends happening and driving the Phenylketonuria market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Phenylketonuria market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Manufacturer Price
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제